A spin-out of the Dutch medical centre, Amsterdam UMC, has raised €5 million in seed funding to take a new cancer vaccine from preclinical development into human trials. CimCure BV has developed a conjugate vaccine that directly targets the tumour endothelium in order to arrest cancer growth. This reportedly unique mechanism of action was highlighted in a paper published in Nature Communications on 23 May 2022.
